Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IL-17
Biotech
MoonLake nanobody boosts ph. 3 endpoints in psoriatic arthritis
At week 16, 42.1% of patients achieved ACR50, and all secondary clinical endpoints were also met in the placebo-controlled study.
Marissa Russo
Aug 10, 2026 11:00am
MoonLake arthritis win kicks off pivotal year for IL-17 nanobody
Feb 23, 2026 5:10am
MoonLake stock sinks as high placebo rate eclipses ph. 3 results
Sep 29, 2025 8:05am
Junshi sees ph. 3 psoriasis win for IL-17 drug, preps China push
Sep 8, 2025 4:54am
MoonLake shines brighter as IL-17 drug scores latest phase 2 win
Nov 6, 2023 8:14am
Acelyrin fails late-phase clinical trial months after $540M IPO
Sep 12, 2023 6:30am
